[go: up one dir, main page]

US20110281805A1 - Use of an ang-(1-7) receptor agonist in acute lung injury - Google Patents

Use of an ang-(1-7) receptor agonist in acute lung injury Download PDF

Info

Publication number
US20110281805A1
US20110281805A1 US13/063,685 US200913063685A US2011281805A1 US 20110281805 A1 US20110281805 A1 US 20110281805A1 US 200913063685 A US200913063685 A US 200913063685A US 2011281805 A1 US2011281805 A1 US 2011281805A1
Authority
US
United States
Prior art keywords
receptor agonist
ang
peptidic
seq
lung
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/063,685
Other languages
English (en)
Inventor
Thomas Walther
Wolfgang Kuebler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Charite Universitaetsmedizin Berlin
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Assigned to CHARITE-UNIVERSITATSMEDIZIN BERLIN reassignment CHARITE-UNIVERSITATSMEDIZIN BERLIN ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: WALTHER, THOMAS, KUEBLER, WOLFGANG
Publication of US20110281805A1 publication Critical patent/US20110281805A1/en
Priority to US13/590,894 priority Critical patent/US8383772B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/085—Angiotensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/14—Angiotensins: Related peptides

Definitions

  • the present invention refers to a peptidic or non-peptidic angiotensin-(1-7) (Ang-(1-7)) receptor agonist, preferably a Mas receptor agonist, for the prevention and/or treatment of acute lung injury, preferably acute respiratory distress syndrome.
  • Ang-(1-7) angiotensin-(1-7) receptor agonist
  • Mas receptor agonist a peptidic or non-peptidic angiotensin-(1-7) receptor agonist
  • ALI acute lung injury
  • ARDS acute respiratory distress syndrome
  • the pathological hallmarks of the disease comprise diffuse alveolo-capillary injury and an increased lung permeability associated with a strong inflammatory response (3,4).
  • the cleavage product of Ang II by ACE2, Ang-(1-7), is not an inert waste product of the angiotensin-pathway, but may exert active biological functions.
  • Ang-(1-7) binds to the G protein-coupled receptor Mas ( 14 ) which appears to be a physiological antagonist of the AT1a receptor ( 15 ), and potentially to other receptors. Binding of Ang-(1-7) to its receptor(s) may thus contribute critically to the previously demonstrated beneficial effects of interventions in the angiotensin pathway on the pathology of ALI/ARDS.
  • the U.S. Pat. No. 6,235,766 refers to non-peptidic agonists of Ang-(1-7) receptors, and particularly discloses 1-(p-thienylbenzyl)imidazoles having a marked action on Ang-(1-7) receptors and mimicking the biological action of the effector hormone Ang-(1-7).
  • the international patent application WO 2006/128266 refers to the interaction between the Mas receptor and Ang-(1-7) or its analogues in the context of controlling the functions of the reproductive system.
  • the international patent application WO 2007/000036 refers to the use of peptidic or non-peptidic Mas receptor agonists and antagonists as apoptotic activity modulators.
  • the international patent application WO 2007/121546 refers to the use of peptidic or non-peptidic Mas receptor agonists for modulating metabolic activities related to the clinical manifestation of the metabolic syndrome or its complications.
  • the object of the present invention is to provide means and methods for a pharmacological intervention in the patho-physiologic events underlying ALI/ARDS.
  • the object of the present invention is solved by an Ang-(1-7) receptor agonist for use in the prevention and/or treatment of an acute lung injury in a subject.
  • the object of the present invention is solved by a method for the prevention and/or treatment of an acute lung injury in a subject using an Ang-(1-7) receptor agonist.
  • the object of the present invention is further solved by a use of an Ang-(1-7) receptor agonist for the preparation of a pharmaceutical composition for the prevention and/or treatment of an acute lung injury in a subject.
  • the object of the present invention is further solved by a method of prevention and/or treatment of an acute lung injury by administering an Ang-(1-7) receptor agonist to a subject.
  • the Ang-(1-7) receptor agonist is a Mas receptor agonist.
  • the Ang-(1-7) receptor agonist interacts with a Mas receptor or a receptor associated with a Mas receptor.
  • the Ang-(1-7) receptor agonist stimulates a receptor that physically interacts with a Mas receptor.
  • the Ang-(1-7) receptor agonist stimulates a receptor that shares pharmacological similarities with a Mas receptor.
  • the Ang-(1-7) receptor agonist is an Ang II metabolite sharing structural similarities with the Ang-(1-7) peptide.
  • the receptor agonist is a peptidic or non-peptidic agonist.
  • the peptidic agonist is an exogenous or endogenous Ang-(1-7) peptide comprising an amino acid sequence Asp 1 -Arg 2 -Val 3 -Tyr 4 -Ile 5 -His 6 -Pro 7 according to SEQ ID NO: 1 or is a derivative or analogue thereof.
  • the peptidic agonist is a derivative or analogue of the Ang-(1-7) peptide, the derivative or analogue comprising an amino acid exchange, deletion or insertion.
  • the derivative or analogue has conserved or better agonistic properties.
  • the peptidic agonist is a derivative or analogue of the Ang-(1-7) peptide, the derivative or analogue comprising an amino acid sequence Asp 1 -Arg 2 -Val 3 -Ser 4 -Ile 5 -His 6 -Pro 7 according to SEQ ID NO: 2, Asp 1 -Arg 2 -Val 3 -Tyr 4 -Ile 5 -His 6 -Cys 7 according to SEQ ID NO: 3 or Asp 1 -Arg 2 -Val 3 -Ser 4 -Ile 5 -His 6 -Cys 7 according to SEQ ID NO: 4.
  • the peptidic agonist is a peptide comprising an amino acid sequence according to SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 4.
  • the peptidic agonist is an exogenous or endogenous NorLeu3-Ang-(1-7) peptide comprising an amino acid sequence Asp 1 -Arg 2 -NorLeu 3 -Tyr 4 -Ile 5 -His 6 -Pro 7 according to SEQ ID NO: 5 or is a derivative or analogue thereof.
  • the peptidic agonist is an exogenous or endogenous Ang IV peptide comprising an amino acid sequence Val 1 -Tyr 2 -Ile 3 -His 4 -Pro 5 -Phe 6 according to SEQ ID NO: 6 or is a derivative or analogue thereof.
  • the peptidic agonist is an exogenous or endogenous Ang III peptide comprising an amino acid sequence Arg 1 -Val 2 -Tyr 3 -Ile 4 -His 5 -Pro 6 -Phe 7 according to SEQ ID NO: 7 or is a derivative or analogue thereof.
  • the non-peptidic agonist is selected from the group of 1-(p-thienylbenzyl)imidazole compounds, and preferably is Ave 0991 (i.e. 5-formyl-4-methoxy-2-phenyl-1-[[4-[2-(ethylaminocarbonylsulfonamido)-5-isobutyl-3-thienyl]phenyl]methyl]-imidazole).
  • the acute lung injury is an acute respiratory distress syndrome.
  • the acute lung injury is related to a pulmonary (direct) or an extrapulmonary (indirect) lung injury.
  • the pulmonary lung injury is selected from the group consisting of inhalation trauma, aspiration trauma, toxic lung oedema, lung infection, preferably pneumonia, lung contusion, and embolism.
  • the extrapulmonary lung damage is associated with a disorder selected from the group consisting of sepsis, systemic inflammatory response syndrome (SIRS), polytrauma, shock, burn, acute pancreatitis, drug intoxication, alcohol abuse, chronic lung disease, mass transfusion, disseminated intravascular coagulation, erythema, and autoimmune lung disease.
  • SIRS systemic inflammatory response syndrome
  • the subject is a mammal, preferably a human, most preferably an adult human.
  • the object of the present invention is further solved by a pharmaceutical composition comprising an Ang-(1-7) receptor agonist for use in the prevention and/or treatment of an acute lung injury in a subject.
  • the object of the present invention is further solved by a method for the prevention and/or treatment of an acute lung injury in a subject using a pharmaceutical composition comprising an Ang-(1-7) receptor agonist.
  • the Ang-(1-7) receptor agonist is a Mas receptor agonist.
  • the receptor agonist is a peptidic or non-peptidic agonist.
  • the peptidic agonist is an Ang-(1-7) peptide comprising an amino acid sequence according to SEQ ID NO: 1 or is a derivative or analogue thereof.
  • the peptidic agonist is a peptide comprising an amino acid sequence according to SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 4.
  • the peptidic agonist is a peptide comprising an amino acid sequence according to SEQ ID NO: 5 or is a derivative or analogue thereof.
  • the peptidic agonist is an Ang IV peptide comprising an amino acid sequence according to SEQ ID NO: 6 or is a derivative or analogue thereof.
  • the peptidic agonist is an Ang III peptide comprising an amino acid sequence according to SEQ ID NO: 7 or is a derivative or analogue thereof.
  • the non-peptidic agonist is selected from the group of 1-(p-thienylbenzyl)imidazole compounds, and preferably is Ave 0991 (i.e. 5-formyl-4-methoxy-2-phenyl-1-[[4-[2-(ethylaminocarbonylsulfonamido)-5-isobutyl-3-thienyl]phenyl]methyl]imidazole).
  • the acute lung injury is an acute respiratory distress syndrome.
  • the acute lung injury is related to a pulmonary (direct) or an extrapulmonary (indirect) lung injury.
  • the pulmonary lung injury is selected from the group consisting of inhalation trauma, aspiration trauma, toxic lung oedema, lung infection, preferably pneumonia, lung contusion, and embolism.
  • the extrapulmonary lung damage is associated with a disorder selected from the group consisting of sepsis, polytrauma, shock, burn, acute pancreatitis, drug intoxication, alcohol abuse, chronic lung disease, mass transfusion, disseminated intravascular coagulation, erythema, and autoimmune lung disease.
  • the subject is a mammal, preferably a human, most preferably an adult human.
  • the pharmaceutical composition is formulated for a parenteral or enteral administration, preferably for a parenteral administration by the route of inhalation, infusion or injection.
  • a pharmaceutical composition formulated for an oral, an intramuscular, an intravenous, a subcutaneous, a topical, a transdermal, a rectal, a vaginal, a pulmonary, an intranasal, an intrabuccal, or a sublingual administration is also considered.
  • the pharmaceutical composition is formulated as a tablet, a pill, a capsule, granules, a syrup, a spray, an aerosol, a liposomal composition, an ointment, a suppository, an implant, a plaster, or a slow release formulation.
  • the pharmaceutical composition further comprises one or more pharmacologically inert and pharmaceutically acceptable excipients such as a polymer carrier, a disintegration agent, a lubricant, a solvent, or a swelling agent.
  • pharmacologically inert and pharmaceutically acceptable excipients such as a polymer carrier, a disintegration agent, a lubricant, a solvent, or a swelling agent.
  • receptor agonist refers to an agent being capable of activating a receptor, i.e. eliciting a receptor response.
  • Ang-(1-7) receptor agonist refers to an agent being capable of activating a receptor that is also activated by Ang-(1-7).
  • Mc receptor agonist refers to an agent being capable of activating the G protein-coupled Mas receptor.
  • Ang-(1-7) signalling is blocked by A779 ([D-Ala 7 -Ang-(1-7); Asp 1 -Arg 2 -Val 3 -Tyr 4 -Ile 5 -His 6 -D-Ala 7 , SEQ ID NO: 8) and/or D-Pro 7 -Ang-(1-7) (Asp 1 -Arg 2 -Val 3 -Tyr 4 -Ile 5 -His 6 -D-Pro 7 , SEQ ID NO: 9), a further characteristic of an Ang-(1-7) agonist is the inhibition of its effects by A779 and/or D-Pro 7 -Ang-(1-7). Further non-competitive or competitive inhibitors are also considered.
  • peptidic agonist refers to a compound comprising one or more peptide bonds.
  • the term encompasses compounds consisting of a pure peptidic structure, i.e. a peptide composed of two or more amino acids, as well as compounds comprising peptidic and non-peptidic structures.
  • non-peptidic agonist refers to a compound not comprising a peptide bond.
  • a compound is of low molecular weight, i.e. a small molecule.
  • derivative means a compound differing from another compound by a structural modification, for example by replacement of one atom or a group of atoms or a functional group with another atom or group of atoms or functional group.
  • analogue means a compound which is similar in structure or function to another compound.
  • exogenous Ang-(1-7) means Ang-(1-7) that is produced outside of the subject's body to be treated and is exogenously applied. This, however, does not exclude that Ang-(1-7) is produced in e.g. a transgenic animal not to be treated. Generally considered is Ang-(1-7) produced by biosynthesis or conventional lab synthesis, e.g. solid-phase synthesis.
  • endogenous Ang-(1-7) means that Ang-(1-7) is endogenously produced by the subject's body to be treated.
  • An (increased) endogenous production of Ang-(1-7) can be the result of a stimulation of its generation from Ang II, e.g. by pharmacologically activating ACE2, by blocking the AT1a receptor, or by inhibiting the degradation of Ang II to Ang III by APA.
  • endogenous Ang-(1-7) production can be increased by stimulation of its generation from Ang I by NEP.
  • An (increased) endogenous production can also be the result of a gene therapeutic intervention, e.g.
  • ACE2 overexpressing ACE2 or a construct that generates directly Ang-(1-7) or one of its precursors.
  • An increased concentration of endogenously produced Ang-(1-7) can also result from a reduced degradation of Ang-(1-7) e.g. by pharmacological inhibition of ACE which degrades Ang-(1-7) to Ang-(1-5).
  • ACE2 Recombinant or overexpressed ACE2 will increase the concentration of Ang-(1-7) directly by stimulating its conversion from Ang II.
  • ACE inhibitors will reduce Ang-(1-7) degradation to Ang-(1-5) while AT1a receptor blockers will increase Ang-(1-7) levels by elevation of ACE2 substrate availability.
  • molecules e.g. peptides or proteins, comprising the Ang-(1-7) peptide sequence or chemical structure.
  • ALI and ARDS are inflammatory disorders of the lung most commonly caused by sepsis, pneumonia, trauma, and/or aspiration. Inflammation can be locally restricted to the lung, or the pulmonary inflammation can be part of a systemic inflammatory process.
  • ALI and ARDS are characterized by hypoxemia and diffuse infiltrates on chest x-ray in the absence of elevated left atrial pressure. ALI and ARDS differ only in the degree of hypoxemia in that ALI is defined as a ratio of arterial oxygen partial pressure over inspiratory oxygen fraction (PaO 2 /FiO 2 ) ⁇ 300 and ARDS as a PaO 2 /FiO 2 ⁇ 200 (16). Diagnosis is by clinical presentation, ABGs (arterial blood gas analyses) and imaging studies. Treatment is with lung-protective, low tidal volume mechanical ventilation, supportive therapy, and treatment of underlying causes.
  • Rats were anesthetized by intraperitoneal injection of medetomidine (0.5 mg/kg bw, Domitor®, Dr. E. Graeub A G, Basel, Switzerland), fentanyl (0.05 mg/kg bw, JanssenCilag, Neuss, Germany) and midazolam (5 mg/kg bw, Dormicum®, Roche, Basel, Switzerland) as previously described (17).
  • medetomidine 0.5 mg/kg bw, Domitor®, Dr. E. Graeub A G, Basel, Switzerland
  • fentanyl 0.05 mg/kg bw, JanssenCilag, Neuss, Germany
  • midazolam 5 mg/kg bw, Dormicum®, Roche, Basel, Switzerland
  • Catheters (internal diameter 0.58 mm; Sims Portex Ltd., Hythe, United Kingdom) were introduced into the left carotid artery and the right internal jugular vein for monitoring of arterial blood pressure (AP), fluid replacement and drug delivery as previously described (18).
  • An ultrasonic flowprobe (Transonic®, Transonic Systems Inc., Ithaca, UY) was placed around the ascending aorta distal to the branching of the coronary arteries for continuous monitoring of cardiac output (CO).
  • CO cardiac output
  • a catheter was introduced via the right ventricle into the pulmonary artery for measurement of pulmonary artery pressure (PAP).
  • AP, PAP and CO were continuously recorded by the software package DasyLab 32 (DasyLab, Moenchengladbach, Germany).
  • Pulmonary vascular resistance (PVR) was calculated as arteriovenous pressure differences over flow under the assumption of a constant left atrial pressure of 2 mmHg.
  • Rats were randomly assigned to four groups of six animals each: Animals in group 1 (control) did not receive any pharmacological interventions.
  • group 2 ALI was induced by intravenous infusion of 0.2 mg/kg oleic acid (Sigma, Kunststoff, Germany) over 30 min in the absence of any treatment.
  • group 3 OA+Ang-(1-7)
  • ALI was induced as in group II, and infusion of Ang-(1-7) at 5 pmol/kg per min was initiated immediately after ALI induction.
  • group 4 (OA+AVE0991)
  • ALI was induced as in group II, and infusion of AVE0991 at 500 pmol/kg per min was initiated immediately after ALI induction.
  • MPO activity was determined by a 3,3′-5,5′-tetramethylbenzidine (TMB)-based photometric assay, compared to appropriate standard curves, and expressed as units per gram lung tissue (U/g).
  • TMB 3,3′-5,5′-tetramethylbenzidine
  • Ang-(1-7) The protective effect of Ang-(1-7) was apparently not attributable to its described vasodilatory effect in systemic blood vessels, since Ang-(1-7) infusion attenuated systemic hypotension in OA-infused rats.
  • the non-peptidic Ang-(1-7) receptor agonist AVE0991 similarly attenuated OA-induced ALI.
  • Additional MPO analyses in groups 4 and 5 indicate that blockade of the Mas receptor by A779 aggravates OA-induced ALI, and blocks the rescue effect of Ang-(1-7) infusion.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Addiction (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
US13/063,685 2008-09-12 2009-09-11 Use of an ang-(1-7) receptor agonist in acute lung injury Abandoned US20110281805A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/590,894 US8383772B2 (en) 2008-09-12 2012-08-21 Ang-(1-7) receptor agonist

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08016142A EP2163259B1 (fr) 2008-09-12 2008-09-12 Utilisation d'agoniste de récepteur Ang-(1-7) pour maladie aiguë du poumon
EP08016142.5 2008-09-12
PCT/EP2009/006619 WO2010028845A2 (fr) 2008-09-12 2009-09-11 Utilisation d'un agoniste du récepteur ang-(1-7) dans une lésion pulmonaire aiguë

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/006619 A-371-Of-International WO2010028845A2 (fr) 2008-09-12 2009-09-11 Utilisation d'un agoniste du récepteur ang-(1-7) dans une lésion pulmonaire aiguë

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/590,894 Continuation US8383772B2 (en) 2008-09-12 2012-08-21 Ang-(1-7) receptor agonist
US13/931,168 Continuation US20140073760A1 (en) 2008-09-12 2013-06-28 Use of an ang-(1-7) receptor agonist in acute lung injury

Publications (1)

Publication Number Publication Date
US20110281805A1 true US20110281805A1 (en) 2011-11-17

Family

ID=40430691

Family Applications (4)

Application Number Title Priority Date Filing Date
US13/063,685 Abandoned US20110281805A1 (en) 2008-09-12 2009-09-11 Use of an ang-(1-7) receptor agonist in acute lung injury
US13/590,894 Expired - Fee Related US8383772B2 (en) 2008-09-12 2012-08-21 Ang-(1-7) receptor agonist
US13/931,168 Abandoned US20140073760A1 (en) 2008-09-12 2013-06-28 Use of an ang-(1-7) receptor agonist in acute lung injury
US14/750,500 Abandoned US20160051621A1 (en) 2008-09-12 2015-06-25 Use of an ang-(1-7) receptor agonist in acute lung injury

Family Applications After (3)

Application Number Title Priority Date Filing Date
US13/590,894 Expired - Fee Related US8383772B2 (en) 2008-09-12 2012-08-21 Ang-(1-7) receptor agonist
US13/931,168 Abandoned US20140073760A1 (en) 2008-09-12 2013-06-28 Use of an ang-(1-7) receptor agonist in acute lung injury
US14/750,500 Abandoned US20160051621A1 (en) 2008-09-12 2015-06-25 Use of an ang-(1-7) receptor agonist in acute lung injury

Country Status (9)

Country Link
US (4) US20110281805A1 (fr)
EP (2) EP2163259B1 (fr)
JP (2) JP2012502071A (fr)
KR (1) KR20110074978A (fr)
CN (2) CN103263661A (fr)
BR (2) BRPI0918443A2 (fr)
CA (1) CA2736922C (fr)
ES (1) ES2393455T3 (fr)
WO (1) WO2010028845A2 (fr)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120321701A1 (en) * 2008-09-12 2012-12-20 Charité-Universitätsmedizin Berlin Ang-(1-7) receptor agonist
WO2013090833A1 (fr) * 2011-12-16 2013-06-20 Tarix Pharmaceuticals Ltd. Angiotensines pour le traitement d'une fibrose
US20130237478A1 (en) * 2012-02-10 2013-09-12 Tarix Pharmaceuticals Ltd. Compositions and methods for treatment of peripheral vascular disease
WO2014055591A1 (fr) * 2012-10-02 2014-04-10 Tarix Pharmaceuticals Ltd. Angiotensine dans le traitement d'états cérébraux
WO2014190152A1 (fr) * 2013-05-24 2014-11-27 Tarix Pharmaceuticals Ltd. Peptides angiotensine dans le traitement du syndrome de marfan et de troubles associés
WO2015054005A1 (fr) * 2013-10-11 2015-04-16 Tarix Pharmaceuticals Ltd. Compositions et méthodes de traitement de maladies associées au bdnf
US20150238560A1 (en) * 2014-02-25 2015-08-27 Tarix Pharmaceuticals Ltd. Methods and compositions for the delayed treatment of stroke
US20160347794A1 (en) * 2014-07-21 2016-12-01 The Arizona Board Of Regents On Behalf Of The University Of Arizona ANG-(1-7) Derivative Oligopeptides and Methods for Using and Producing the Same
US20170304391A1 (en) * 2014-07-21 2017-10-26 Arizona Board Of Regents On Behalf Of The University Of Arizona ANG-(1-7) Derivative Oligopeptides for the Treatment of Pain and Other Indications
WO2018204385A1 (fr) * 2017-05-02 2018-11-08 Beth Israel Deaconess Medical Center, Inc. Polythérapie contre le cancer
WO2022165189A1 (fr) * 2021-01-28 2022-08-04 Capacity Bio, Inc. Procédés et agents qui stimulent le renouvellement mitochondrial pour traiter une maladie

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102532265A (zh) * 2011-12-29 2012-07-04 中国人民解放军第四军医大学 一种短肽、其异构体及其应用
US8557958B1 (en) 2012-06-18 2013-10-15 Tarix Pharmaceuticals Ltd. Compositions and methods for treatment of diabetes
RU2015108678A (ru) * 2012-09-17 2016-11-10 Терикс Фармасьютикалз Лтд. Составы ангиотензина для перорального применения
WO2014189634A1 (fr) * 2013-04-19 2014-11-27 University Of Iowa Research Foundation Angiotensines dans la dystrophie musculaire
CN107073295A (zh) * 2014-07-17 2017-08-18 南加利福尼亚大学 用于治疗肌骨病的方法、化合物和组合物
JP7010698B2 (ja) * 2015-04-08 2022-01-26 コーニンクレッカ フィリップス エヌ ヴェ 急性呼吸促迫症候群（ａｒｄｓ）のリスクスコアによって導かれる換気治療推薦のためのツール
WO2018129511A2 (fr) * 2017-01-09 2018-07-12 Arizona Board Of Regents On Behalf Of The University Of Arizona Oligopeptides dérivés de l'ang (1-7) pour le traitement d'une lésion cérébrale traumatique et d'autres déficiences cognitives
CN112316107B (zh) * 2019-07-17 2023-01-06 首都医科大学附属北京妇产医院 血管紧张素(1-7)在胰腺疾病中的应用
WO2021183863A1 (fr) * 2020-03-13 2021-09-16 Constant Therapeutics Llc Procédés et compositions pour le traitement d'une infection par le coronavirus
WO2022094025A1 (fr) * 2020-10-30 2022-05-05 Gere Dizerega Angiotensine 1-7 pour le traitement de la covid-19
EP4085921A1 (fr) 2021-05-04 2022-11-09 CU-Pharmaceuticals UG Angiotensine-(1-7) dans le traitement des maladies liées au sras-cov

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6110895A (en) * 1996-12-16 2000-08-29 University Of Southern California Method of promoting healing in skin grafts
YU78601A (sh) 1999-05-05 2005-07-19 Aventis Pharma Deutschland Gmbh. 1-(p-tienilbenzil)-imidazoli kao agonisti angiotenzin-(1-7)- receptora, postupak za njihovu proizvodnju, njihova primena i farmaceutski preparati koji ih sadrže
WO2003072059A2 (fr) * 2002-02-27 2003-09-04 Wake Forest University L'angiotensine-(1-7) et agonistes de l'angiotensine-(1-7) pour l'inhibition de la croissance de cellules cancereuses
US20050119180A1 (en) * 2002-03-28 2005-06-02 Roks Antonius J.M. Use of angiotensin 1-7 for enhancing cardiac function
EP1723962A1 (fr) * 2005-05-19 2006-11-22 IMBA-Institut für Molekulare Biotechnologie GmbH Utilisation des inhibiteurs du système de rénine-angiotensine pour le traitement des lesions poumonaires.
BRPI0503122A (pt) 2005-05-30 2007-05-02 Univ Minas Gerais composições farmacêuticas do peptìdeo angiotensina-(1-7) [ang-(1-7)] e seus análogos, agonistas e antagonistas usando as ciclodextrinas, seus derivados, e o polìmeros biodegradáveis e/ou dos produtos derivados para uso no controle das funções do sistema reprodutivo
BRPI0502497A (pt) 2005-06-28 2007-02-06 Univ Minas Gerais uso de agonistas e antagonistas do receptor acoplado a proteìna g, mas, como moduladores de atividade apoptótica para o estudo, a prevenção e o tratamento de doenças
BRPI0602366B1 (pt) 2006-04-26 2017-12-12 Universidade Federal De Minas Gerais Use of agonists of the receptor coupled to protein g, but, in the treatment of metabolic syndrome, its components and their complications
WO2008130217A1 (fr) * 2006-08-08 2008-10-30 Applied Nanosystems B.V. Analogues d'angiotensines cycliques
EP2163259B1 (fr) * 2008-09-12 2012-06-13 Charité-Universitätsmedizin Berlin (Charité) Utilisation d'agoniste de récepteur Ang-(1-7) pour maladie aiguë du poumon

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8383772B2 (en) * 2008-09-12 2013-02-26 Charite Universitatsmedizin Berlin Ang-(1-7) receptor agonist
US20120321701A1 (en) * 2008-09-12 2012-12-20 Charité-Universitätsmedizin Berlin Ang-(1-7) receptor agonist
WO2013090833A1 (fr) * 2011-12-16 2013-06-20 Tarix Pharmaceuticals Ltd. Angiotensines pour le traitement d'une fibrose
US20130237478A1 (en) * 2012-02-10 2013-09-12 Tarix Pharmaceuticals Ltd. Compositions and methods for treatment of peripheral vascular disease
RU2661109C2 (ru) * 2012-10-02 2018-07-11 Терикс Фармасьютикалз Лтд. Ангиотензин в лечении состояний головного мозга
WO2014055591A1 (fr) * 2012-10-02 2014-04-10 Tarix Pharmaceuticals Ltd. Angiotensine dans le traitement d'états cérébraux
US9511055B2 (en) 2012-10-02 2016-12-06 Tarix Pharmaceuticals Ltd. Angiotensin in treating brain conditions
CN105451756A (zh) * 2013-05-24 2016-03-30 塔瑞克斯制药有限公司 在治疗马凡氏综合征及其相关病症中的血管紧张素肽
US9107870B2 (en) 2013-05-24 2015-08-18 Tarix Phamaceuticals Ltd. Angiotensin peptides in treating marfan syndrome and related disorders
WO2014190152A1 (fr) * 2013-05-24 2014-11-27 Tarix Pharmaceuticals Ltd. Peptides angiotensine dans le traitement du syndrome de marfan et de troubles associés
US20160296591A1 (en) * 2013-10-11 2016-10-13 Tarix Pharmaceuticals Ltd. Compositions and methods for treatment of bdnf-related conditions
WO2015054005A1 (fr) * 2013-10-11 2015-04-16 Tarix Pharmaceuticals Ltd. Compositions et méthodes de traitement de maladies associées au bdnf
US20150238560A1 (en) * 2014-02-25 2015-08-27 Tarix Pharmaceuticals Ltd. Methods and compositions for the delayed treatment of stroke
US9333233B2 (en) * 2014-02-25 2016-05-10 Tarix Pharmaceuticals Ltd. Methods and compositions for the delayed treatment of stroke
US20160347794A1 (en) * 2014-07-21 2016-12-01 The Arizona Board Of Regents On Behalf Of The University Of Arizona ANG-(1-7) Derivative Oligopeptides and Methods for Using and Producing the Same
US20170304391A1 (en) * 2014-07-21 2017-10-26 Arizona Board Of Regents On Behalf Of The University Of Arizona ANG-(1-7) Derivative Oligopeptides for the Treatment of Pain and Other Indications
US9670251B2 (en) * 2014-07-21 2017-06-06 The Arizona Board Of Regents On Behalf Of The University Of Arizona ANG-(1-7) derivative oligopeptides and methods for using and producing the same
US10183055B2 (en) * 2014-07-21 2019-01-22 Arizona Board Of Regents On Behalf Of The University Of Arizona Ang-(1-7) derivative oligopeptides for the treatment of pain and other indications
US10550156B2 (en) 2014-07-21 2020-02-04 Arizona Board Of Regents On Behalf Of The University Of Arizona Ang (1-7) derivative oligopeptides and methods for using and producing the same
US10881708B2 (en) 2014-07-21 2021-01-05 Arizona Board Of Regents On Behalf Of The University Of Arizona Ang (1-7) derivative oligopeptides for the treatment of pain
US11104706B2 (en) 2014-07-21 2021-08-31 Arizona Board Of Regents On Behalf Of The University Of Arizona Ang (1-7) derivative oligopeptides and methods for using and producing the same
US12116423B2 (en) 2014-07-21 2024-10-15 Arizona Board Of Regents On Behalf Of The University Of Arizona Ang (1-7) derivative oligopeptides and methods for using and producing the same
WO2018204385A1 (fr) * 2017-05-02 2018-11-08 Beth Israel Deaconess Medical Center, Inc. Polythérapie contre le cancer
WO2022165189A1 (fr) * 2021-01-28 2022-08-04 Capacity Bio, Inc. Procédés et agents qui stimulent le renouvellement mitochondrial pour traiter une maladie
US12343331B2 (en) 2021-01-28 2025-07-01 Capacity Bio, Inc. Methods and agents that stimulate mitochondrial turnover for treating disease

Also Published As

Publication number Publication date
US20120321701A1 (en) 2012-12-20
CN103263661A (zh) 2013-08-28
ES2393455T3 (es) 2012-12-21
US20160051621A1 (en) 2016-02-25
BRPI0918443A2 (pt) 2015-11-24
JP2012502071A (ja) 2012-01-26
WO2010028845A3 (fr) 2010-06-10
HK1161100A1 (en) 2012-08-24
CN102164614B (zh) 2014-03-26
US20140073760A1 (en) 2014-03-13
EP2341938A2 (fr) 2011-07-13
BR122013002187A2 (pt) 2016-04-05
CA2736922C (fr) 2014-08-19
US8383772B2 (en) 2013-02-26
CN102164614A (zh) 2011-08-24
CA2736922A1 (fr) 2010-03-18
JP5881122B2 (ja) 2016-03-09
JP2014074048A (ja) 2014-04-24
WO2010028845A2 (fr) 2010-03-18
KR20110074978A (ko) 2011-07-05
EP2163259A1 (fr) 2010-03-17
EP2163259B1 (fr) 2012-06-13

Similar Documents

Publication Publication Date Title
CA2736922C (fr) Utilisation d'un agoniste du recepteur ang-(1-7) dans une lesion pulmonaire aigue
Xu et al. ACE2/ANG-(1–7)/Mas pathway in the brain: the axis of good
Santos et al. Pharmacological effects of AVE 0991, a nonpeptide angiotensin‐(1–7) receptor agonist
Juillerat-Jeanneret The other angiotensin II receptor: AT2R as a therapeutic target
EP2986308B1 (fr) Angiotensine ii en association pour le traitement de l'hypertension
JP2019508378A (ja) 昇圧薬の投与方法
Katovich et al. Angiotensin-(1-7) as an antihypertensive, antifibrotic target
JP2019501201A (ja) アンジオテンシンｉｉの投与方法
Wen et al. Reduction of infarct size by orally administered des-aspartate-angiotensin I in the ischemic reperfused rat heart
HK1161100B (en) Use of an ang-(1-7) receptor agonist in acute lung injury
JP5477794B2 (ja) エンドキニンｃ／ｄ由来のペプチド
US20140296143A1 (en) Angiotensin-(1-7) As A Chemoprevention Agent
Höcht et al. Therapeutic perspectives of angiotensin-(1-7) in the treatment of cardiovascular disease
Butler et al. Effects of ANG II and III and angiotensin receptor blockers on nasal salt gland secretion and arterial blood pressure in conscious Pekin ducks (Anas platyrhynchos)
Yokota et al. Cardioprotective effects of an angiotensin-converting-enzyme inhibitor, imidapril, and Ca2+ channel antagonist, amlodipine, in spontaneously hypertensive rats at established stage of hypertension
Physiologically et al. Regulation of cardiovascular remodeling by the counter-regulatory axis of the renin–angiotensin system
US20150105329A1 (en) Methods and Pharmaceutical Compositions for Prevention or Treatment of Ischemia Related Organ Damage
WO2015155323A1 (fr) Antagoniste du br2 destiné à être utilisé dans la prévention de l'effet hypotensif chez un patient traité avec des inhibiteurs de l'enzyme convertissant l'angiotensine (acei)
Ferrario Corcoran Lecture
Ortiz et al. Knockout of ACE-N facilitates improved cardiac function after myocardial infarction
Greco Analysis of cardiovascular responses to major products of angiotensin-converting enzyme and angiotensin-converting enzyme 2
Shenoy et al. Conflict of interest: None Correspondence to
Suadicani et al. Reversal of diabetic vasculopathy in a rat model of

Legal Events

Date Code Title Description
AS Assignment

Owner name: CHARITE-UNIVERSITATSMEDIZIN BERLIN, GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:WALTHER, THOMAS;KUEBLER, WOLFGANG;SIGNING DATES FROM 20110408 TO 20110412;REEL/FRAME:026857/0686

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION